



PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 61387

Title: Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture

Reviewer's code: 05275248

Position: Peer Reviewer

Academic degree: PhD

Professional title: Academic Research, Dean

Reviewer's Country/Territory: China

Author's Country/Territory: Japan

Manuscript submission date: 2020-12-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-12-28 11:04

Reviewer performed review: 2021-01-03 11:03

Review time: 5 Days and 23 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

The combination of chemotherapeutic drugs and angiogenesis inhibitors can expand the therapeutic window of drugs and effectively inhibit tumor growth without obvious toxicity. Results of the pivotal Phase III “VELOUR” study on the anticancer drug ZALTRAP (aflibercept) showed that AFL+FOLFIRI significantly improved overall survival, progression-free survival, and overall tumor response rate in patients with metastatic colorectal cancer who have previously received oxaliplatin-containing therapy. This manuscript mainly compared the efficacy and safety profiles of AFL in the second-line and salvage therapy settings of CRC patients. This research has certain clinical guiding significance, but still have some deficiencies as following: 1. In this study, the author mentioned three different angiogenesis inhibitors, but there is currently no evidence to suggest which AIs to choose in combination with FOLFIRI has the best efficacy. This is also a good point with promising clinical value. If possible, the authors could follow up relevant multi-center joint clinical trials. 2. Only 41 cases were included in this study, sample size was too small to be convincing. It is recommended to expand the sample size and analyze whether the results are consistent. 3. Data showed that AFL has a similar safety and efficacy in the salvage therapy setting as in the second-line setting. Whether other AIs drugs have similar safety and effects in these two groups? Compared with others, what are the advantages of choosing AFL?



RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 61387

Title: Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture

Reviewer's code: 05275248

Position: Peer Reviewer

Academic degree: PhD

Professional title: Academic Research, Dean

Reviewer's Country/Territory: China

Author's Country/Territory: Japan

Manuscript submission date: 2020-12-28

Reviewer chosen by: Jia-Ru Fan

Reviewer accepted review: 2021-01-29 10:32

Reviewer performed review: 2021-01-29 10:40

Review time: 1 Hour

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent [] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) [] Minor revision [] Major revision [] Rejection
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous [] Onymous Conflicts-of-Interest: [] Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

This version of MS is acceptable.